<?xml version="1.0" encoding="UTF-8"?>
<p>Patients received three fixed-dose combination tablets (each containing 100 mg of glecaprevir and 40 mg of pibrentasvir), administered orally once daily with food. Treatment duration was 8 weeks for patients without cirrhosis, 12 weeks for patients with compensated cirrhosis and 16 weeks for treatment-experienced GT3 patients, according to label. As recommended by current guidelines, patients with decompensated cirrhosis were not treated with G/P in order to avoid a potential toxicity of protease inhibitors in these patients[
 <xref rid="pone.0229239.ref034" ref-type="bibr">34</xref>].
</p>
